

pCODR Public Posting of Funding Decisions

May 30, 2013

Hello,

In July 2011, the pan-Canadian Oncology Drug Review began accepting submissions from pharmaceutical manufacturers and clinician-based tumour groups. As of March 31, 2013, pCODR completed 13 reviews and had another 13 submissions under review. As part of our on-going commitment to greater transparency and clarity in the cancer review process, pCODR has started to summarize the funding decisions made by the participating provinces. These are now publicly posted on our website.

As committed by the pCODR Steering Committee and led by our provincial partners, we have summarized the funding decisions made by each province for all drugs/indications where a “Notification to Implement” a final recommendation has been issued by pCODR. The summary for each drug/indication lists each province, their funding decision, the date of their decision and the funding criteria (if applicable). Any changes to the summaries will be updated at the end of every month and publicly accessible on the pCODR’s website under the “Find a Review” tab and listed according to each drug.

pCODR provides consistency and clarity to the cancer drug review process and ensures that all provinces and cancer agencies (excluding Quebec) benefit from a single, clear approach to new cancer drug evaluation, benefiting from the same evidence and principles to ensure provinces and territories have the best possible information to base their funding decisions. There are many factors that go into a province’s (or cancer agency’s) decision to fund an oncology drug. These include, but are not limited to, available budget, regional health system priorities and local program design. A pCODR recommendation is one of several factors considered prior to a funding decision.

I welcome your comments about this recent transparency initiative or any other aspect of the review process.

Sincerely,



Mona Sabharwal
Executive Director